SCHEMBL3883330

SCHEMBL3883330

CCCn1ccc2cc(-c3cc(CCC(=O)O)ccc3OCC3CCCC3)ccc21

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.45
PPARG P37231 3/20 0.44
NR1H2 P55055 2/20 0.44
PPARD Q03181 2/20 0.44
PPARA Q07869 2/20 0.44
NR1H3 Q13133 2/20 0.44
THRA P10827 1/20 0.42
THRB P10828 1/20 0.42
S1PR1 P21453 2/20 0.41
TP53 P04637 1/20 0.37
MDM2 Q00987 1/20 0.37
FFAR1 O14842 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
OXER1 Q8TDS5 1/20 0.35
GRM2 Q14416 1/20 0.35
P2RX3 P56373 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3882068 0.95 FFAR4 (0.47) FFAR4PPARGNR1H2PPARDPPARA
SCHEMBL3881653 0.93 THRA (0.43) FFAR4PPARGNR1H2PPARDPPARA
SCHEMBL3683810 0.92 FFAR4 (0.47) FFAR4PPARGNR1H2PPARDPPARA
SCHEMBL3881703 0.90 THRA (0.44) FFAR4PPARGNR1H2PPARDPPARA
SCHEMBL3884556 0.89 THRA (0.44) FFAR4THRATHRBS1PR1TP53
SCHEMBL3882968 0.89 THRA (0.46) FFAR4THRATHRBS1PR1FFAR1
SCHEMBL3883317 0.88 PPARG (0.45) FFAR4PPARGNR1H2PPARDPPARA
SCHEMBL3880670 0.87 PPARG (0.45) FFAR4PPARGNR1H2PPARDPPARA
SCHEMBL3881933 0.87 FFAR4 (0.43) FFAR4PPARGNR1H2PPARDPPARA
SCHEMBL3883706 0.85 THRA (0.42) FFAR4PPARGNR1H2PPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 FFAR4 115/4885PPARG 59/4885NR1H2 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.